Houlihan WJ, Lee ML, Munder PG, Nemecek GM, Handley DA, Winslow CM, Happy J, Jaeggi C. Antitumor activity of SRI 62-834, a cyclic ether analog of ET-18-OCH3.
Lipids 1987;
22:884-90. [PMID:
2832680 DOI:
10.1007/bf02535549]
[Citation(s) in RCA: 39] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
SRI 62-834, an analog of the antitumor agent ET-18-OCH3 in which the oxygen atom at carbon atom 2 has been incorporated into a five-membered heterocycle, has been prepared and evaluated as an antitumor agent. The compound exhibited good cytotoxicity in vitro against a variety of tumor cell lines and was as effective as ET-18-OCH3 given orally in the mouse Meth A sarcoma model. SRI 62-834 was shown to be an inhibitor of platelet-derived growth factor (PDGF), possibly at the receptor level, and platelet-activating factor (PAF) at the receptor level.
Collapse